Trials
1 active
4 in total · 3 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “OMS906 study drug repeat-dose 5mg/kg IV administration at 8-week intervals”In the company’s words, NCT06298955 on ClinicalTrials.gov
- Tested for
- Paroxysmal Nocturnal Hemoglobinuria
- Main trialPhase 2
- “The purpose of this study is to assess the long-term safety and tolerability of repeat-dose OMS906 5 mg/kg IV administration at 8-week intervals in patients with PNH.”In the company’s words, NCT06298955 on ClinicalTrials.gov
- Other names
- zaltenibart
Other drugs for Paroxysmal Nocturnal Hemoglobinuria
Coming up1
- DecPhase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | Dec 2026 | Long-Term Safety, Tolerability and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Completed | 10 Oct 2024 | Safety and Efficacy of OMS906 in Paroxysmal Nocturnal Hemoglobinuria Patients With a Sub-optimal Response to Ravulizumab | |
| Phase 2Terminated | 14 Apr 2026 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | |
| Phase 1Completed | 3 Nov 2025 | Study of the Safety and Efficacy of OMS906 in Patients With Paroxysmal Nocturnal Hemoglobinuria |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026